Other small molecules with HDAC inhibitor properties, such as suberoylanilide hydroxamic acid (SAHA/Vorinostat) [112], trichostatin A [113], and resveratrol [114], also demonstrated success in laboratory models of SMA but have not advanced to clinical trials. This evidence concerns the gene HDAC9 and proximal spinal muscular atrophy.